Evidence map›Paper›PMID 40324795›Full record

ArticleDrug testing and analysis2025

Surface Wipe Sampling of Hazardous Medicinal Products: A European Interlaboratory Comparison Study.

Roland B van den Berg, Ewelina Korczowska, Mónica S F Santos, Maria Francisca Portilha-Cunha, Ana R L Ribeiro, Lucie Bláhová, Luděk Bláha, Claudia Vom Eyser, Jochen Tuerk, Richard C J M van Rossen and 2 more

Abstract readComparative Study
In one paragraph

Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Roland B van den BergDepartment of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-2285-781X
Ewelina KorczowskaDepartment of Hospital Pharmacy, University Clinical Hospital, Poznan, Poland.
Mónica S F SantosEPIUnit ITR, Institute of Public Health of the University Porto, University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0001-8684-0147
Maria Francisca Portilha-CunhaLEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0001-7069-0500
Ana R L RibeiroALiCE-Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0002-4445-5379
Lucie BláhováRECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
Luděk BláhaRECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-7314-7455
Claudia Vom EyserInstitut für Umwelt & Energie, Technik & Analytik e. V. (IUTA), Duisburg, Germany.
Jochen TuerkInstitut für Umwelt & Energie, Technik & Analytik e. V. (IUTA), Duisburg, Germany.ORCID https://orcid.org/0000-0002-9972-277X
Richard C J M van RossenApotheek Haagse Ziekenhuizen, The Hague, the Netherlands.
Erik B WilmsApotheek Haagse Ziekenhuizen, The Hague, the Netherlands.ORCID https://orcid.org/0000-0002-7116-7794
Mirjam CrulDepartment of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-4929-2388

Funding

European Society of Oncology Pharmacy (ESOP)FCT/MCTES (PIDDAC) LA/P/0045/2020FCT/MCTES (PIDDAC) UIDB/00511/2020FCT/MCTES (PIDDAC) UIDB/50020/2020FCT/MCTES (PIDDAC) UIDP/00511/2020FCT/MCTES (PIDDAC) UIDP/50020/2020Foundation for Science and Technology (FCT) 2021.05219.BDFoundation for Science and Technology (FCT) LA/P/0064/2020Foundation for Science and Technology (FCT) UIDB/04750/2020Ministry of Education, Youth and Sports LM2023069
6 · The paper itself

Abstract

Workplace monitoring of hazardous medicinal products (HMPs) using surface wipe sampling is becoming common practice in many European hospitals and pharmacies. However, no independent quality control is available to validate wiping procedures and analytical methods. This study aimed to conduct a Europe-wide interlaboratory comparison (ILC) program to independently and blindly assess laboratory performance and variability in HMP detection. Four European laboratories participated in the study. Six HMPs-cyclophosphamide, etoposide, gemcitabine, ifosfamide, methotrexate, and paclitaxel-were prepared at four concentrations (5000, 2000, 200, and 20 ng/mL) and applied to a 400-cm

Indexed as

Hazardous SubstancesCyclophosphamideEtoposideEuropeGemcitabineHumansLaboratoriesMethotrexateOccupational ExposurePharmaceutical PreparationsQuality ControlCyclophosphamideEtoposideGemcitabineHazardous SubstancesMethotrexatePharmaceutical Preparationsanalytical methodantineoplastic drugsquality controlsurface contaminationworkplace monitoring

Identifiers

PMID40324795
PMCPMC12489289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.